

BIOLASE, INC
Form 4
February 12, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
FEINBERG LARRY N

(Last) (First) (Middle)
200 GREENWICH AVENUE
(Street)
GREENWICH, CT 06830
(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLASE, INC [BIOL]

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2014

4. If Amendment, Date Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___X___ 10% Owner
___ Officer (give title below) ___ Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	V	Amount	(A) or (D)	Price			
Common Stock, par value \$0.001 per share	02/10/2014		P		4,000	A	\$ 2.53	979,452	I	See footnote (1) (4)
Common Stock, par value \$0.001 per share	02/10/2014		P		320,000	A	\$ 2.57	1,299,452	I	See footnote (1) (4)
Common Stock, par	02/10/2014		P		18,335	A	\$ 2.53	2,801,939	I	See footnote

Edgar Filing: BIOLASE, INC - Form 4

value								(2) (4)
\$0.001 per share								
Common Stock, par value	02/10/2014	P	1,345,525	A	\$ 2.57	4,147,464	I	See footnote (2) (4)
\$0.001 per share								
Common Stock, par value	02/10/2014	P	2,500	A	\$ 2.53	313,794	I	See footnote (3) (4)
\$0.001 per share								
Common Stock, par value	02/10/2014	P	280,000	A	\$ 2.57	593,794	I	See footnote (3) (4)
\$0.001 per share								
Common Stock, par value	02/11/2014	P	5,300	A	\$ 2.69	1,304,752	I	See footnote (1) (4)
\$0.001 per share								
Common Stock, par value	02/11/2014	P	22,044	A	\$ 2.69	4,169,508	I	See footnote (2) (4)
\$0.001 per share								
Common Stock, par value	02/11/2014	P	2,500	A	\$ 2.69	596,294	I	See footnote (3) (4)
\$0.001 per share								
Common Stock, par value	02/12/2014	P	6,200	A	\$ 2.59	1,310,952	I	See footnote (1) (4)
\$0.001 per share								
Common Stock, par value	02/12/2014	P	25,729	A	\$ 2.59	4,195,237	I	See footnote (2) (4)
\$0.001 per share								
Common Stock, par value	02/12/2014	P	2,900	A	\$ 2.59	599,194	I	See footnote (3) (4)

\$0.001 per share

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned (Instr. 5)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
FEINBERG LARRY N 200 GREENWICH AVENUE GREENWICH, CT 06830		X		

Signatures

/s/ Larry N. Feinberg
Date: 02/12/2014

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These securities are owned by Oracle Ten Fund Master, L.P. ("Ten Fund").
 - (2) These securities are owned by Oracle Partners, L.P. ("Partners").
 - (3) These securities are owned by Oracle Institutional Partners, L.P. ("Institutional Partners").

Edgar Filing: BIOLASE, INC - Form 4

- The Reporting Person serves as the managing member of Oracle Associates, LLC, the general partner of Partners and Institutional Partners, and accordingly, may be deemed to be the indirect beneficial owner of the shares beneficially owned by Partners and
- (4) Institutional Partners. Mr. Feinberg is the sole shareholder, director and president of Oracle Investment Management, Inc., which serves as investment manager to Ten Fund, and accordingly, may be deemed to be the beneficial owner of the shares beneficially owned by Ten Fund. Mr. Feinberg disclaims beneficial ownership of all such shares except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.